智通财经网·2025-10-14 10:20Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug SAF-189, an innovative small molecule chemical drug intended for treating non-small cell lung cancer (NSCLC) [1] Group 1 - The drug SAF-189 was primarily aimed at treating ALK+ and ROS1+ non-small cell lung cancer [1] - The registration application for SAF-189 was accepted by the NMPA in March 2025 for treating locally advanced or metastatic NSCLC patients with ALK positivity [1] - The withdrawal of the registration application does not signify the termination of the project; Fosun Wanguo plans to enhance the registration materials according to the latest technical requirements from the NMPA and will resubmit the application promptly [1] Group 2 - The withdrawal of the registration application is not expected to have a significant impact on the current performance of the group, which includes the company and its subsidiaries [1]